Patent application number | Description | Published |
20080269234 | INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE - Inhibitors of poly(ADP-ribose)polymerase, ways to make them and methods of treating patients using them are disclosed. | 10-30-2008 |
20090030016 | BENZIMIDAZOLE POLY(ADP RIBOSE)POLYMERASE INHIBITORS - Compounds which inhibit the activity of poly(ADP-ribose)polymerase (PARP), compositions containing the compounds and methods of treating diseases using them are disclosed. | 01-29-2009 |
20090186877 | SUBSTITUTED 1H-BENZIMIDAZOLE-4-CARBOXAMIDES ARE POTENT PARP INHIBITORS - The present invention relates to 1H-benzimidazole-4-carboxamides of formula (I), | 07-23-2009 |
20100234425 | 2-SUBSTITUTED-1H-BENZIMIDAZOLE-4-CARBOXAMIDES ARE PARP INHIBITORS - Compounds of Formula (I) | 09-16-2010 |
20110257187 | PHTHALAZIN-(2H)-ONE INHIBITORS OF KINASES - The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, | 10-20-2011 |
20110257189 | PYRROLOPYRAZINONE INHIBITORS OF KINASES - The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, | 10-20-2011 |
20120046303 | BENZIMIDAZOLE POLY(ADP RIBOSE)POLYMERASE INHIBITORS - Compounds which inhibit the activity of poly(ADP-ribose)polymerase (PARP), compositions containing the compounds and methods of treating diseases using them are disclosed. | 02-23-2012 |
20140212509 | INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE - Inhibitors of poly(ADP-ribose)polymerase, ways to make them and methods of treating patients using them are disclosed. | 07-31-2014 |
20140213610 | PYRAZOLOQUINOLONES ARE POTENT PARP INHIBITORS - Compounds of Formula (I) | 07-31-2014 |
20140275027 | PYRROLO[2,3-B]PYRIDINE CDK9 KINASE INHIBITORS - Disclosed are compounds of Formula (IIIa), | 09-18-2014 |
20140296235 | 1H-BENZIMIDAZOLE-4-CARBOXAMIDES SUBSTITUTED WITH PHENYL AT THE 2-POSITION ARE POTENT PARP INHIBITORS - Compounds having formula (I) | 10-02-2014 |
20150218165 | TETRACYCLIC CDK9 KINASE INHIBITORS - Disclosed are compounds of Formula (Ia), and pharmaceutically acceptable salts thereof, | 08-06-2015 |
Patent application number | Description | Published |
20090069594 | Process and Catalyst for Oxidizing Aromatic Compounds - Catalytic compositions for conversion of substituted aromatic feed materials to oxidized products comprising aromatic carboxylic acid derivatives of the substituted aromatic feed materials comprise at least two metal or metalloid elements, at least one of which is palladium, platinum, vanadium or titanium, and at least one of which is a Group 5, 6, 14 or 15 metal or metalloid. A process for oxidizing substituted aromatic feed materials comprises contacting the feed material with oxygen in the presence of such a catalytic composition in a liquid reaction mixture. | 03-12-2009 |
20090088585 | Process and Catalyst for Oxidizing Aromatic Compounds - Catalytic compositions for conversion of substituted aromatic feed materials to oxidized products comprising aromatic carboxylic acid derivatives of the substituted aromatic feed materials comprise a combination comprising a palladium component, an antimony component and/or a bismuth component, and one or more Group 4, 5, 6 or 14 metal or metalloid components. A process for oxidizing substituted aromatic feed materials comprises contacting the feed material with oxygen in the presence of such a catalytic composition in a liquid reaction mixture. | 04-02-2009 |
20090118536 | Process for the Production of Aromatic Carboxylic Acids in Water - A process is disclosed for producing at least one aromatic carboxylic acid by contacting a liquid reaction mixture comprising an aromatic feedstock and water with oxygen in the presence of a bromine-free metal catalyst composition wherein the metal catalyst composition has activity in the absence of bromine for oxidation of the aromatic feedstock with at least 80% conversion to oxidized aromatic derivatives of the aromatic feedstock and with at least 80% selectivity to the aromatic carboxylic acid. This process operates in water without the use of bromine at temperatures and residence times substantially the same as conventional processes for aromatic carboxylic acid manufacture, as well as with less total burning and with yields to product equivalent or higher than conventional processes. | 05-07-2009 |
20090124829 | Terephthalic Acid Composition and Process for the Production Thereof - Terephthalic acid is prepared by reacting a 2,5-furandicarboxylate with ethylene in the presence of a solvent to produce a bicyclic ether; and then dehydrating the bicyclic ether. The process of the present invention effectively produces terephthalic acid, while reducing or eliminating the impurities, color bodies and carbon oxides produced in commercial practice by the liquid-phase oxidation of methyl-substituted benzene feedstocks. | 05-14-2009 |
20100145094 | Process and Catalyst for Oxidizing Aromatic Compounds - Catalytic compositions for conversion of substituted aromatic feed materials to oxidized products comprising aromatic carboxylic acid derivatives of the substituted aromatic feed materials comprise solid particles comprising palladium in combination with at least one of antimony, bismuth and gold, and optionally, an additional metal or metalloid component effective to promote activity or selectivity of the palladium and antimony, bismuth or gold for oxidation to aromatic carboxylic acids. A process for oxidizing substituted aromatic feed materials comprises contacting the feed material with oxygen in the presence of such catalytic compositions in a liquid reaction mixture. | 06-10-2010 |
Patent application number | Description | Published |
20080306074 | Compositions Comprising Addl Receptors, Related Compositions, and Related Methods - Disclosed and claimed herein are compositions comprising ADDL receptors, related compositions, and related methods. ADDL receptors are typically, but perhaps not exclusively, localized at the post-synaptic density (PSD) of neuronal cells. Related compositions include, but are not limited to, compounds that affect, positively or negatively, ADDL binding to neuronal cells, either via one or more receptors localized at the post-synaptic density (PSD) or otherwise. Related methods include, but are not limited to, procedures to screen for compounds that affect, either positively or negatively, ADDL binding to neuronal cells, either via one or more receptors localized at the post-synaptic density (PSD) or otherwise. Other related methods include, but are not limited to, prevention and treatment of ADDL-related diseases, such as Alzheimer's disease, mild cognitive impairment, Down's syndrome, and the like, using compositions that inhibit, block, or otherwise interfere with ADDL binding to one or more receptors localized at the post-synaptic density of neuronal cells. | 12-11-2008 |
Patent application number | Description | Published |
20120266560 | Self-counterboring, screw-threaded headed fastener with enlarged flanged portion or wings having cutting teeth thereon, and cutting wrench/screw gun sockets - A self-counterboring screw-threaded headed fastener, for the threaded insertion into an underlying fixed support or substrate in order to fixedly secure a structural component, such as, for example, an insulated metal panel (IMP), to the underlying fixed support or substrate without the need for pre-drilling a bore within the insulated metal panel (IMP), in order to accommodate the screw-threaded head of the fastener, prior to the insertion of the screw-threaded fastener into and through the insulated metal panel (IMP) for fixation within and to the underlying fixed support or substrate, is disclosed. Cutting wrench or screw-gun sockets are also disclosed for similar purposes. | 10-25-2012 |
20130089389 | FASTENER WITH LOW PROFILE HEAD AND WASHER - A fastener assembly is provided with a fastener and a washer. The fastener includes a low profile head coupled to a shaft, wherein the low profile head has an underside and an outwardly facing side opposite from the underside. The outwardly facing side has a tapered portion surrounding a central flat portion having a drive recess. The underside has a washer recess disposed about the shaft and configured to hold or accomodate a washer. | 04-11-2013 |
20130280013 | THERMAL BREAK FASTENER - A thermal break fastener includes a head that has a top side and an underside. The head has diameter. A shank depends from the underside of the head and has an end that has a longitudinal bore therein, opposite the head. The shank is formed from a thermally non-transmissive material. The shank has a diameter less than the diameter of the head. A seal is positioned on the shank. A driving/boring element has a driving point and a self-counter-bore cutter spaced from the driving point. The self-counter-bore cutter has a diameter about equal to the diameter of the shank. The driving/boring element is mounted to the shank with the self-counter-bore cutter disposed at about the end of the shank opposite the head. A two-piece configuration includes a driving/boring element including a self-counter-bore cutter and a separate a sealing head with a seal positioned on the sealing head. | 10-24-2013 |
Patent application number | Description | Published |
20110064811 | Solid forms of N-[2,4-BIS(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline- -3-carboxamide - The present invention relates to solid state forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1), pharmaceutical compositions thereof and methods therewith. | 03-17-2011 |
20120157470 | SALTS AND CRYSTALLINE FORMS OF AN APOPTOSIS-INDUCING AGENT - Salts and crystalline forms of 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}-sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide are suitable active pharmaceutical ingredients for pharmaceutical compositions useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer. | 06-21-2012 |
20120214841 | SOLID FORMS OF N-[2,4-BIS(1,1-DIMETHYLETHYL)-5-HYDROXYPHENYL]-1,4-DIHYDRO-4-OXOQUINOLINE- -3-CARBOXAMIDE - The present invention relates to solid state forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1), pharmaceutical compositions thereof and methods therewith. | 08-23-2012 |
20130317060 | Solid Forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline- -3-carboxamide - The present invention relates to solid state forms of N—[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1), pharmaceutical compositions thereof and methods therewith. | 11-28-2013 |
20140018518 | CRYSTALINE FORMS OF HCV INHIBITOR - The present invention features crystalline forms of Compound I. In one embodiment, a crystalline form of Compound I has characteristic peaks in the PXRD pattern at values of two theta (° 2θ) of 10.7, 11.6, 12.7, 13.0, 13.2, 13.7, 14.5, 18.7, 19.0, and 19.9 after equilibration at 43% relative humidity. | 01-16-2014 |
20140213596 | SALTS AND CRYSTALLINE FORMS OF AN APOPTOSIS-INDUCING AGENT - Salts and crystalline forms of 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}-sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide are suitable active pharmaceutical ingredients for pharmaceutical compositions useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer. | 07-31-2014 |
20140242172 | Solid Forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline- -3-carboxamide - The present invention relates to solid state forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1), pharmaceutical compositions thereof and methods therewith. | 08-28-2014 |
20150073031 | ATRASENTAN MANDELATE SALTS - The present disclosure relates to: (a) mandelate salts of atrasentan, (b) pharmaceutical compositions comprising an atrasentan mandelate salt, and, optionally, one or more additional therapeutic agents; (b) methods of using an atrasentan mandelate salt to treat nephropathy, chronic kidney disease, and/or other conditions; (c) kits comprising a first pharmaceutical composition comprising an atrasentan mandelate salt, and, optionally, a second pharmaceutical composition comprising one or more additional therapeutic agents; (d) methods for the preparation of an atrasentan mandelate salt; and (e) atrasentan mandelate salts prepared by such method. | 03-12-2015 |
20150126574 | ATRASENTAN MANDELATE SALTS - The present disclosure relates to: (a) mandelate salts of atrasentan, (b) pharmaceutical compositions comprising an atrasentan mandelate salt, and, optionally, one or more additional therapeutic agents; (b) methods of using an atrasentan mandelate salt to treat nephropathy, chronic kidney disease, and/or other conditions; (c) kits comprising a first pharmaceutical composition comprising an atrasentan mandelate salt, and, optionally, a second pharmaceutical composition comprising one or more additional therapeutic agents; (d) methods for the preparation of an atrasentan mandelate salt; and (e) atrasentan mandelate salts prepared by such method. | 05-07-2015 |
20150175612 | CRYSTAL FORMS - The present invention features crystalline forms of Compound I. In one embodiment, a crystalline form of Compound I has characteristic peaks in the PXRD pattern at values of two theta (°2θ) of 6.0, 6.7, 10.4, 11.9, 17.5, 17.7, 21.5, 22.0, 22.7, and 24.2. | 06-25-2015 |